Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations and Business Activities (Details)

Nature of Operations and Business Activities (Details)					3 Months Ended						9 Months Ended
Nature of Operations and Business Activities (Details)	Aug. 18, 2023 USD ($) $ / shares	Aug. 15, 2023 USD ($) $ / shares shares	Feb. 16, 2023 USD ($) $ / shares shares	Nov. 10, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Jul. 24, 2023 USD ($)	Jan. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Nature Of Operations And Business Activities [Line Items]
Working capital deficit					$ (1,567,627)						$ (1,567,627)
Accumulated deficit					99,962,619						99,962,619				$ 66,737,765
Cash and cash equivalents					5,126,245			$ 415,389			5,126,245	$ 415,389
Operating loss					24,705,766			2,922,282			30,648,916	9,028,662
Net loss					24,945,834	$ 3,111,500	$ 5,167,520	$ 3,127,283	$ 3,419,278	$ 3,043,399	33,224,854	$ 9,589,960
Estimate for legal contingency					6,212,319						6,212,319			$ 6,212,319	$ 6,205,310
Coverage received to cover legal expenses					$ 5,000,000						$ 5,000,000
Exercise price (in dollars per share) \| $ / shares					$ 25.00						$ 25.00
Number of EHT warrants outstanding (in shares) \| shares			0
Number of Warrants Vested and Outstanding (in shares) \| shares					3,280,940						3,280,940
Bird Rock Bio Sub, Inc. (BRB)
Nature Of Operations And Business Activities [Line Items]
Equity interest issued or issuable (in shares) \| shares							5,436,378
Business combination, consideration transferred, equity interests issued and issuable	$ 21,609,586
Business combination, consideration transferred, equity interests issued and issuable, par value \| $ / shares	$ 0.001
Bridge Loan
Nature Of Operations And Business Activities [Line Items]
Debt, face amount													$ 250,000
MTA Warrants, Credit Consideration
Nature Of Operations And Business Activities [Line Items]
Common stock issuance costs			$ 1,597,236								$ 1,597,236
Common Stock Warrants \| MTA Warrants
Nature Of Operations And Business Activities [Line Items]
Exercise price (in dollars per share) \| $ / shares			$ 282,905		$ 282,905						$ 282,905
August 2023 PIPE Financing Common Stock Warrants
Nature Of Operations And Business Activities [Line Items]
Exercise price (in dollars per share) \| $ / shares		$ 5.16			$ 5.16						$ 5.16
Number of Warrants Vested and Outstanding (in shares) \| shares					2,325,537						2,325,537
Class Of Warrant or Right, Issued, Acquisition \| shares		2,989,981
Proceeds from Issuance or Sale of Equity		$ 11,734,947
Discontinued Operations, Disposed of by Sale \| Verdelite SPA
Nature Of Operations And Business Activities [Line Items]
Aggregate purchase price				$ 9,451,233
Proceeds from asset sale, net of legal expenses				$ 5,532,266
Emerald Health Therapeutics, Inc.
Nature Of Operations And Business Activities [Line Items]
Exchange ratio				1.95
Bird Rock Bio Sub, Inc. (BRB)
Nature Of Operations And Business Activities [Line Items]
Underlying common stock price (in dollars per share) \| $ / shares	$ 5.16